Novel Therapeutic Approaches and Targets for the Treatment of Neutrophilic Dermatoses, Management of Patients with Neutrophilic Dermatoses and Future Directions in the Era of Biologic Treatment

Author(s): Elisa Molinelli*, Valerio Brisigotti, Matteo Paolinelli, Annamaria Offidani

Journal Name: Current Pharmaceutical Biotechnology

Volume 22 , Issue 1 , 2021


Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Neutrophilic dermatoses are a heterogeneous group of inflammatory skin disorders characterized by the presence of a sterile, predominantly neutrophilic infiltrate on histopathology. Universally accepted and validated guidelines for the management of neutrophilic dermatoses do not exist, also given the paucity of randomized controlled study and high-quality data. However, the literature on the effective use of biologic therapies is rapidly expanding. This article reviews the epidemiology, clinical characteristics, histopathologic features, and management of pyoderma gangrenosum as well as Sweet’s syndrome, sub-corneal pustular dermatoses and bowel-associated dermatosis arthritis syndrome. The use of biologic agents, including tumor necrosis factor α-inhibitors, anti-IL1, anti-IL-17, and IL-23 are discussed in detail.

Keywords: Bowel-associated dermatosis arthritis syndrome, neutrophilic dermatoses, pyoderma gangrenosum, Sweet`s syndrome, subcorneal pustular dermatoses, anti TNF, ustekinumab, secukinumab

[1]
Sweet, R.D. An acute febrile neutrophilic dermatosis. Br. J. Dermatol., 1964, 76, 349-356.
[http://dx.doi.org/10.1111/j.1365-2133.1964.tb14541.x] [PMID: 14201182]
[2]
Prat, L.; Bouaziz, J.D.; Wallach, D.; Vignon-Pennamen, M.D.; Bagot, M. Neutrophilic dermatoses as systemic diseases. Clin. Dermatol., 2014, 32(3), 376-388.
[http://dx.doi.org/10.1016/j.clindermatol.2013.11.004] [PMID: 24767185]
[3]
Navarini, A.A.; Satoh, T.K.; French, L.E. Neutrophilic dermatoses and autoinflammatory diseases with skin involvement--innate immune disorders. Semin. Immunopathol., 2016, 38(1), 45-56.
[http://dx.doi.org/10.1007/s00281-015-0549-6] [PMID: 26620372]
[4]
Ashchyan, H.J.; Nelson, C.A.; Stephen, S.; James, W.D.; Micheletti, R.G.; Rosenbach, M. Neutrophilic dermatoses: Pyoderma gangrenosum and other bowel-and arthritis-associated neutrophilic dermatoses. J. Am. Acad. Dermatol., 2018, 79(6), 1009-1022.
[http://dx.doi.org/10.1016/j.jaad.2017.11.063] [PMID: 29653213]
[5]
Cohen, P.R. Neutrophilic dermatoses: A review of current treatment options. Am. J. Clin. Dermatol., 2009, 10(5), 301-312.
[http://dx.doi.org/10.2165/11310730-000000000-00000] [PMID: 19658442]
[6]
Brunsting, L.A.; Goeckermann, W.H.; O’Leary, P.A. Pyoderma (ecthyma) gangrenosum: Clinical and experimental observation in five cases occurring in adults. Arch. Dermatol., 1930, 22, 655-680.
[7]
Ashchyan, H.J.; Butler, D.C.; Nelson, C.A.; Noe, M.H.; Tsiaras, W.G.; Lockwood, S.J.; James, W.D.; Micheletti, R.G.; Rosenbach, M.; Mostaghimi, A. The association of age with clinical presentation and comorbidities of Pyoderma gangrenosum. JAMA Dermatol., 2018, 154(4), 409-413.
[http://dx.doi.org/10.1001/jamadermatol.2017.5978] [PMID: 29450453]
[8]
Ahronowitz, I.; Harp, J.; Shinkai, K. Etiology and management of Pyoderma gangrenosum: A comprehensive review. Am. J. Clin. Dermatol., 2012, 13(3), 191-211.
[http://dx.doi.org/10.2165/11595240-000000000-00000] [PMID: 22356259]
[9]
Crowson, A.N.; Mihm, M.C. Jr, Magro, C. Pyoderma gangrenosum: A review. J. Cutan. Pathol., 2003, 30(2), 97-107.
[http://dx.doi.org/10.1034/j.1600-0560.2003.00024.x] [PMID: 12641787]
[10]
Braswell, S.F.; Kostopoulos, T.C.; Ortega-Loayza, A.G. Pathophysiology of Pyoderma gangrenosum (PG): An updated review. J. Am. Acad. Dermatol., 2015, 73(4), 691-698.
[http://dx.doi.org/10.1016/j.jaad.2015.06.021] [PMID: 26253362]
[11]
Marzano, A.V.; Fanoni, D.; Antiga, E. Expression of cytokines, chemokines and other effector molecules in two prototypic autoinflammatory skin diseases, Pyoderma gangrenosum and Sweet’s syndrome. Clin. Exp. Immunol., 2014, 178(1), 48-56.
[http://dx.doi.org/10.1111/cei.12394] [PMID: 24903614]
[12]
DeFilippis, E.M.; Feldman, S.R.; Huang, W.W. The genetics of Pyoderma gangrenosum and implications for treatment: A systematic review. Br. J. Dermatol., 2015, 172(6), 1487-1497.
[http://dx.doi.org/10.1111/bjd.13493] [PMID: 25350484]
[13]
Ruocco, E.; Sangiuliano, S.; Gravina, A.G.; Miranda, A.; Nicoletti, G. Pyoderma gangrenosum: An updated review. J. Eur. Acad. Dermatol. Venereol., 2009, 23(9), 1008-1017.
[http://dx.doi.org/10.1111/j.1468-3083.2009.03199.x] [PMID: 19470075]
[14]
Miller, J.; Yentzer, B.A.; Clark, A.; Jorizzo, J.L.; Feldman, S.R. Pyoderma gangrenosum: A review and update on new therapies. J. Am. Acad. Dermatol., 2010, 62(4), 646-654.
[http://dx.doi.org/10.1016/j.jaad.2009.05.030] [PMID: 20227580]
[15]
Lee, G.L.; Chen, A.Y. Neutrophilic dermatoses: Kids are not just little people. Clin. Dermatol., 2017, 35(6), 541-544.
[http://dx.doi.org/10.1016/j.clindermatol.2017.08.005] [PMID: 29191346]
[16]
Cozzani, E.; Gasparini, G.; Parodi, A. Pyoderma gangrenosum: A systematic review. G. Ital. Dermatol. Venereol., 2014, 149(5), 587-600.
[PMID: 25213386]
[17]
Molinelli, E.; Paolinelli, M.; Campanati, A.; Brisigotti, V.; Offidani, A. Metabolic, pharmacokinetic, and toxicological issues surrounding dapsone. Expert Opin. Drug Metab. Toxicol., 2019, 15(5), 367-379.
[http://dx.doi.org/10.1080/17425255.2019.1600670] [PMID: 30943794]
[18]
Reichrath, J.; Bens, G.; Bonowitz, A.; Tilgen, W. Treatment recommendations for Pyoderma gangrenosum: An evidence-based review of the literature based on more than 350 patients. J. Am. Acad. Dermatol., 2005, 53(2), 273-283.
[http://dx.doi.org/10.1016/j.jaad.2004.10.006] [PMID: 16021123]
[19]
Ahn, C.; Negus, D.; Huang, W. Pyoderma gangrenosum: A review of pathogenesis and treatment. Expert Rev. Clin. Immunol., 2018, 14(3), 225-233.
[http://dx.doi.org/10.1080/1744666X.2018.1438269] [PMID: 29406827]
[20]
Reguiaï, Z.; Grange, F. The role of anti-tumor necrosis factor-alpha therapy in Pyoderma gangrenosum associated with inflammatory bowel disease. Am. J. Clin. Dermatol., 2007, 8(2), 67-77.
[http://dx.doi.org/10.2165/00128071-200708020-00002] [PMID: 17428111]
[21]
Partridge, A.C.R.; Bai, J.W.; Rosen, C.F.; Walsh, S.R.; Gulliver, W.P.; Fleming, P. Effectiveness of systemic treatments for Pyoderma gangrenosum: A systematic review of observational studies and clinical trials. Br. J. Dermatol., 2018, 179(2), 290-295.
[http://dx.doi.org/10.1111/bjd.16485] [PMID: 29478243]
[22]
Brooklyn, T.N.; Dunnill, M.G.; Shetty, A. Infliximab for the treatment of Pyoderma gangrenosum: A randomised, double blind, placebo controlled trial. Gut, 2006, 55(4), 505-509.
[http://dx.doi.org/10.1136/gut.2005.074815] [PMID: 16188920]
[23]
Argüelles-Arias, F.; Castro-Laria, L.; Lobatón, T. Characteristics and treatment of Pyoderma gangrenosum in inflammatory bowel disease. Dig. Dis. Sci., 2013, 58(10), 2949-2954.
[http://dx.doi.org/10.1007/s10620-013-2762-2] [PMID: 23828140]
[24]
Regueiro, M.; Valentine, J.; Plevy, S.; Fleisher, M.R.; Lichtenstein, G.R. Infliximab for treatment of Pyoderma gangrenosum associated with inflammatory bowel disease. Am. J. Gastroenterol., 2003, 98(8), 1821-1826.
[http://dx.doi.org/10.1111/j.1572-0241.2003.07581.x] [PMID: 12907338]
[25]
Ljung, T.; Staun, M.; Grove, O.; Fausa, O.; Vatn, M.H.; Hellström, P.M. Pyoderma gangrenosum associated with crohn disease: Effect of TNF-alpha blockade with infliximab. Scand. J. Gastroenterol., 2002, 37(9), 1108-1110.
[http://dx.doi.org/10.1080/003655202320378338] [PMID: 12374238]
[26]
Kechichian, E.; Haber, R.; Mourad, N.; El Khoury, R.; Jabbour, S.; Tomb, R. Pediatric Pyoderma gangrenosum: A systematic review and update. Int. J. Dermatol., 2017, 56(5), 486-495.
[http://dx.doi.org/10.1111/ijd.13584] [PMID: 28233293]
[27]
Stiegler, J.D.; Lucas, C.T.; Sami, N. Pyoderma gangrenosum in pregnancy successfully treated with infliximab and prednisone. JAAD Case Rep., 2017, 3(5), 387-389.
[http://dx.doi.org/10.1016/j.jdcr.2017.03.016] [PMID: 28879220]
[28]
Rousset, L.; de Masson, A.; Begon, E. Tumor necrosis factor-α inhibitors for the treatment of Pyoderma gangrenosum not associated with inflammatory bowel diseases: A multicenter retrospective study. J. Am. Acad. Dermatol., 2019, 80(4), 1141-1143.
[http://dx.doi.org/10.1016/j.jaad.2018.10.006] [PMID: 30342166]
[29]
Patel, F.; Fitzmaurice, S.; Duong, C. Effective strategies for the management of Pyoderma gangrenosum: A comprehensive review. Acta Derm. Venereol., 2015, 95(5), 525-531.
[http://dx.doi.org/10.2340/00015555-2008] [PMID: 25387526]
[30]
Campanati, A.; Brisigotti, V.; Ganzetti, G. Finally, recurrent Pyoderma gangrenosum treated with Adalimumab: case report and review of the literature. J. Eur. Acad. Dermatol. Venereol., 2015, 29(6), 1245-1247.
[http://dx.doi.org/10.1111/jdv.12703] [PMID: 25200926]
[31]
Sagami, S.; Ueno, Y.; Tanaka, S.; Nagai, K.; Hayashi, R.; Chayama, K. Successful use of adalimumab for treating Pyoderma gangrenosum with ulcerative colitis under corticosteroid-tapering conditions. Intern. Med., 2015, 54(17), 2167-2172.
[http://dx.doi.org/10.2169/internalmedicine.54.4853] [PMID: 26328641]
[32]
Lee, J.H.; Chang, I.K.; Lee, H.E. Im, M.; Seo, Y.-J.; Lee, J.-H.; Lee, Y. Treatment of recalcitrant Pyoderma gangrenosum with ulcerative colitis by adalimumab injection. Ann. Dermatol., 2017, 29(2), 260-262.
[http://dx.doi.org/10.5021/ad.2017.29.2.260] [PMID: 28392668]
[33]
Herberger, K.; Dissemond, J.; Brüggestrat, S.; Sorbe, C. Augustin. Biologics and immunoglobulins in the treatment of Pyoderma gangrenosum - analysis of 52 patients. J. Dtsch. Dermatol. Ges., 2019, 17(1), 32-41.
[34]
Bardazzi, F.; Magnano, M.; Tengattini, V.; Loi, C. Pyoderma gangrenosum in the genital area: Successful treatment using adalimumab. Eur. J. Dermatol., 2018, 28(2), 263-264.
[http://dx.doi.org/10.1684/ejd.2018.3224] [PMID: 29378677]
[35]
Afifi, L.; Sanchez, I.M.; Wallace, M.M.; Braswell, S.F.; Ortega-Loayza, A.G.; Shinkai, K. Diagnosis and management of peristomal Pyoderma gangrenosum: A systematic review. J. Am. Acad. Dermatol., 2018, 78(6), 1195-1204.e1.
[http://dx.doi.org/10.1016/j.jaad.2017.12.049] [PMID: 29288099]
[36]
De Wet, J.; Jordaan, H.F.; Kannenberg, S.M.; Tod, B.; Glanzmann, B.; Visser, W.I. Pyoderma gangrenosum, acne, and suppurative hidradenitis syndrome in end-stage renal disease successfully treated with adalimumab.Dermatol Online J , 2017, 23(12)13030/qt82d4m2zw.
[PMID: 29447652]
[37]
Sood, A.K.; McShane, D.B.; Googe, P.B.; Wu, E.Y. Successful treatment of PAPA syndrome with Dual adalimumab and tacrolimus therapy. J. Clin. Immunol., 2019, 39(8), 832-835.
[http://dx.doi.org/10.1007/s10875-019-00685-6] [PMID: 31471736]
[38]
Lee, H.; Park, S.H.; Kim, S.K.; Choe, J.Y.; Park, J.S. Pyogenic arthritis, Pyoderma gangrenosum, and Acne Syndrome (PAPA syndrome) with E250K mutation in CD2BP1 gene treated with the tumor necrosis factor inhibitor adalimumab. Clin. Exp. Rheumatol., 2012, 30(3), 452.
[PMID: 22513199]
[39]
Murphy, B.; Morrison, G.; Podmore, P. Successful use of adalimumab to treat Pyoderma gangrenosum, Acne and Suppurative Hidradenitis (PASH syndrome) following colectomy in ulcerative colitis. Int. J. Colorectal Dis., 2015, 30(8), 1139-1140.
[http://dx.doi.org/10.1007/s00384-014-2110-9] [PMID: 25564349]
[40]
Kim, F.S.; Pandya, A.G. The use of etanercept in the treatment of peristomal Pyoderma gangrenosum. Clin. Exp. Dermatol., 2012, 37(4), 442-443.
[http://dx.doi.org/10.1111/j.1365-2230.2011.04234.x] [PMID: 22582915]
[41]
Haridas, V.; Shetty, P.; Dsouza, L.C.; Dinesh, U.S.; Haridas, K.; Bargale, A. Pyoderma gangrenosum in Sjögren’s syndrome and its successful treatment with topical application of etanercept. Int. J. Rheum. Dis., 2017, 20(5), 657-659.
[http://dx.doi.org/10.1111/1756-185X.13086] [PMID: 28419761]
[42]
Ben Abdallah, H.; Fogh, K.; Bech, R. Pyoderma gangrenosum and tumour necrosis factor alpha inhibitors: A semi-systematic review. Int. Wound J., 2019, 16(2), 511-521.
[http://dx.doi.org/10.1111/iwj.13067] [PMID: 30604927]
[43]
Hurabielle, C.; Schneider, P.; Baudry, C.; Bagot, M.; Allez, M.; Viguier, M. Certolizumab pegol - A new therapeutic option for refractory disseminated Pyoderma gangrenosum associated with Crohn’s disease. J. Dermatolog. Treat., 2016, 27(1), 67-69.
[http://dx.doi.org/10.3109/09546634.2015.1034075] [PMID: 25909366]
[44]
Diotallevi, F.; Campanati, A.; Radi, G. Pyoderma gangrenosum successfully treated with golimumab: Case report and review of the literature. Dermatol. Ther. (Heidelb.), 2019, 32(4)e12928
[http://dx.doi.org/10.1111/dth.12928] [PMID: 30980454]
[45]
Guenova, E.; Teske, A.; Fehrenbacher, B. Interleukin 23 expression in Pyoderma gangrenosum and targeted therapy with ustekinumab. Arch. Dermatol., 2011, 147(10), 1203-1205.
[http://dx.doi.org/10.1001/archdermatol.2011.168] [PMID: 21680759]
[46]
Greb, J.E.; Gottlieb, A.B.; Goldminz, A.M. High-dose Ustekinumab for the treatment of severe, recalcitrant Pyoderma gangrenosum. Dermatol. Ther. (Heidelb.), 2016, 29(6), 482-483.
[http://dx.doi.org/10.1111/dth.12387] [PMID: 27502191]
[47]
Nunes, G.; Patita, M.; Fernandes, V. Refractory Pyoderma gangrenosum in a patient with Crohn’s Disease: Complete response to Ustekinumab. J. Crohn’s Colitis, 2019, 13(6), 812-813.
[http://dx.doi.org/10.1093/ecco-jcc/jjy200] [PMID: 30535292]
[48]
Goldminz, A.M.; Botto, N.C.; Gottlieb, A.B. Severely recalcitrant Pyoderma gangrenosum successfully treated with Ustekinumab. J. Am. Acad. Dermatol., 2012, 67(5), e237-e238.
[http://dx.doi.org/10.1016/j.jaad.2012.04.045] [PMID: 23062936]
[49]
Nieto, D.; Sendagorta, E.; Rueda, J.M.; Herranz, P. Successful treatment with Ustekinumab and vacuum-assisted closure therapy in recalcitrant myelodysplastic syndrome-associated Pyoderma gangrenosum: Case report and literature review. Clin. Exp. Dermatol., 2019, 44(1), 116-119.
[http://dx.doi.org/10.1111/ced.13679] [PMID: 29851121]
[50]
de Risi-Pugliese, T.; Seksik, P.; Bouaziz, J.D. Ustekinumab-Crohn’s Disease-Neutrophilic Dermatosis Study Group. Ustekinumab treatment for neutrophilic dermatoses associated with Crohn’s disease: A multicenter retrospective study. J. Am. Acad. Dermatol., 2019, 80(3), 781-784.
[http://dx.doi.org/10.1016/j.jaad.2018.06.065] [PMID: 30003991]
[51]
Moreno, García M; Madrid, González M; Prada, Lobato JM. Secukinumab for Pyoderma gangrenosum: A case report. Med. Clin. (Barc.), 2019, 152(6), 246.
[http://dx.doi.org/10.1016/j.medcli.2018.06.011] [PMID: 30144933]
[52]
Lipsker, D.; Lenormand, C. Indications and modes of use for interleukin (IL)-1 antagonists in inflammatory dermatosis: A new therapeutic approach to immune-mediated inflammatory diseases. Ann. Dermatol. Venereol., 2012, 139(6-7), 459-467.
[http://dx.doi.org/10.1016/j.annder.2012.03.012] [PMID: 22721478]
[53]
Kineret (Anakinra) Swedish Orphan Biovitrum AB (publ) SE-112 76 Stockholm. Sweden 2019.
[54]
Brenner, M.; Ruzicka, T.; Plewig, G.; Thomas, P.; Herzer, P. Targeted treatment of Pyoderma gangrenosum in PAPA (pyogenic arthritis, Pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor.antagonist anakinra Br. J. Dermatol., 2009, 161(5), 1199-1201.
[http://dx.doi.org/10.1111/j.1365-2133.2009.09404.x] [PMID: 19673875]
[55]
Mercuri, S.R.; Paolino, G.; De Flammineis, E.; Didona, D.; Brianti, P. Successful treatment of Pyoderma gangrenosum with anakinra in a patient with Wiskott-Aldrich syndrome. Dermatol. Ther. (Heidelb.), 2018, 31(2)e12582
[http://dx.doi.org/10.1111/dth.12582] [PMID: 29214738]
[56]
Jennings, L.; Molloy, O.; Quinlan, C.; Kelly, G.; O’Kane, M. Treatment of Pyoderma gangrenosum, Acne, Suppurative Hidradenitis (PASH) with weight-based anakinra dosing in a hepatitis B carrier. Int. J. Dermatol., 2017, 56(6), e128-e129.
[http://dx.doi.org/10.1111/ijd.13528] [PMID: 28239847]
[57]
Beynon, C.; Chin, M.F.; Hunasehally, P. Successful treatment of autoimmune disease-associated Pyoderma gangrenosum with the IL-1 receptor antagonist Anakinra: A case series of 3 patients. J. Clin. Rheumatol., 2017, 23(3), 181-183.
[http://dx.doi.org/10.1097/RHU.0000000000000511] [PMID: 28333874]
[58]
Lachmann, H.J.; Kone-Paut, I.; Kuemmerle-Deschner, J.B. Canakinumab in CAPS Study Group. Canakinumab in CAPS Study Group. Use of canakinumab in the cryopyrin-associated periodic syndrome. N. Engl. J. Med., 2009, 360(23), 2416-2425.
[http://dx.doi.org/10.1056/NEJMoa0810787] [PMID: 19494217]
[59]
Kolios, A.G.; Maul, J.T.; Meier, B. Canakinumab in adults with steroid-refractory Pyoderma gangrenosum. Br. J. Dermatol., 2015, 173(5), 1216-1223.
[http://dx.doi.org/10.1111/bjd.14037] [PMID: 26471257]
[60]
Sun, N.Z.; Ro, T.; Jolly, P.; Sayed, C.J. Non-response to interleukin-1 antagonist canakinumab in two patients with refractory Pyoderma gangrenosum and Hidradenitis suppurativa. J. Clin. Aesthet. Dermatol., 2017, 10(9), 36-38.
[PMID: 29344326]
[61]
Fujimoto, N.; Yamasaki, Y.; Watanabe, R. Paradoxical uveitis and Pyoderma gangrenosum in a patient with psoriatic arthritis under infliximab treatment. J. Dtsch. Dermatol. Ges., 2018, 16(9), 1139-1140.
[http://dx.doi.org/10.1111/ddg.13632] [PMID: 30129996]
[62]
Vestita, M.; Guida, S.; Mazzoccoli, S.; Loconsole, F.; Foti, C. Late paradoxical development of Pyoderma gangrenosum in a psoriasis patient treated with infliximab. Eur. J. Dermatol., 2015, 25(3), 272-273.
[http://dx.doi.org/10.1684/ejd.2015.2526] [PMID: 25786592]
[63]
Brunasso, A.M.; Laimer, M.; Massone, C. Paradoxical reactions to targeted biological treatments: A way to treat and trigger? Acta Derm. Venereol., 2010, 90(2), 183-185.
[http://dx.doi.org/10.2340/00015555-0777] [PMID: 20169304]
[64]
Company-Quiroga, J.; Alique-García, S.; Martínez-Morán, C.; Khedaoui, R.; Romero-Maté, A.; Borbujo, J. Adalimumab-induced Pyoderma gangrenosum in a patient with hidradenitis suppurativa: A paradoxical reaction. Indian J. Dermatol. Venereol. Leprol., 2019, 85(4), 422-425.
[http://dx.doi.org/10.4103/ijdvl.IJDVL_277_18] [PMID: 31115357]
[65]
Kowalzick, L.; Bertolini, J.; Baumann, C.; Walther, B.; Truhm, B.; Eickenscheidt, L. Paradoxical reaction to etanercept: Development of Pyoderma gangraenosum during therapy of psoriasis arthritis. J. Dtsch. Dermatol. Ges., 2013, 11(5), 447-449.
[http://dx.doi.org/10.1111/ddg.12032] [PMID: 23343137]
[66]
Jin, K.; Matsuzaki, Y.; Akasaka, E.; Nakano, H.; Sawamura, D. Pyoderma gangrenosum triggered by switching from adalimumab to secukinumab. J. Dermatol., 2019, 46(3), e108-e109.
[http://dx.doi.org/10.1111/1346-8138.14611] [PMID: 30192400]
[67]
Rahier, J.F.; Lion, L.; Dewit, O.; Lambert, M. Regression of Sweet’s syndrome associated with Crohn’s disease after anti-tumour necrosis factor therapy. Acta Gastroenterol. Belg., 2005, 68(3), 376-379.
[PMID: 16268426]
[68]
Foster, E.N.; Nguyen, K.K.; Sheikh, R.A.; Prindiville, T.P. Crohn’s disease associated with Sweet’s syndrome and Sjögren’s syndrome treated with infliximab. Clin. Dev. Immunol., 2005, 12(2), 145-149.
[http://dx.doi.org/10.1080/17402520500134254] [PMID: 16050146]
[69]
Vanbiervliet, G.; Anty, R.; Schneider, S.; Arab, K.; Rampal, P.; Hebuterne, X. Sweet’s syndrome and erythema nodosum associated with Crohn’s disease treated by infliximab. Gastroenterol. Clin. Biol., 2002, 26(3), 295-297.
[PMID: 11981477]
[70]
Rappaport, A.; Shaked, M.; Landau, M.; Dolev, E. Sweet’s syndrome in association with Crohn’s disease: Report of a case and review of the literature. Dis. Colon Rectum, 2001, 44(10), 1526-1529.
[http://dx.doi.org/10.1007/BF02234611] [PMID: 11598485]
[71]
Castro-Fernández, M.; Sánchez-Muñoz, D.; Ruíz-Granados, E.; Merchante, N.; Corzo, J. Coexistence of Pyoderma gangrenosum and Sweet’s syndrome in a patient with ulcerative colitis. Am. J. Gastroenterol., 2007, 102(12), 2865-2866.
[http://dx.doi.org/10.1111/j.1572-0241.2007.01528_8.x] [PMID: 18042124]
[72]
Patel, A.V.; Jotwani, P.M.; Sultan, K.S. Azathioprine-induced sweet syndrome treated with infliximab. Am. J. Ther., 2019, 26(5), e616-e6167.
[http://dx.doi.org/10.1097/MJT.0000000000000820] [PMID: 30074533]
[73]
Moreno, Márquez C,; Maldonado, Pérez B; Castro, Laria L Infliximab as rescue treatment in Sweet’s Syndrome related to corticodependent ulcerative colitis. J. Crohn’s Colitis, 2018, 12(6), 755-756.
[http://dx.doi.org/10.1093/ecco-jcc/jjy018] [PMID: 29474532]
[74]
Malheiros, A.P.; Teixeira, M.G.; Takahashi, M.D.; de Almeida, M.G.; Kiss, D.R.; Cecconello, I. Sweet syndrome associated with ulcerative colitis. Inflamm. Bowel Dis., 2007, 13(12), 1583-1584.
[http://dx.doi.org/10.1002/ibd.20227] [PMID: 17636566]
[75]
Smith, S.E.; Gillon, J.T.; Ferguson, S.B. Targetoid palmoplantar Sweet syndrome as presenting sign of severe Crohn’s disease. J. Am. Acad. Dermatol., 2013, 69(4), e199-e200.
[http://dx.doi.org/10.1016/j.jaad.2013.04.056] [PMID: 24034402]
[76]
Matzkies, F.G.; Manger, B.; Schmitt-Haendle, M. Severe septicaemia in a patient with polychondritis and Sweet’s syndrome after initiation of treatment with infliximab. Ann. Rheum. Dis., 2003, 62(1), 81-82.
[http://dx.doi.org/10.1136/ard.62.1.81] [PMID: 12480678]
[77]
Drone, E.R.; McCrory, A.L.; Lane, N.; Fiala, K. Disseminated nocardiosis in a patient on infliximab and methylprednisolone for treatment-resistant Sweet’s syndrome. Indian Dermatol. Online J., 2014, 5(3), 300-302.
[http://dx.doi.org/10.4103/2229-5178.137782] [PMID: 25165648]
[78]
Agarwal, A.; Barrow, W.; Selim, M.A.; Nicholas, M.W. Refractory subcutaneous sweet syndrome treated with adalimumab. JAMA Dermatol., 2016, 152(7), 842-844.
[http://dx.doi.org/10.1001/jamadermatol.2016.0503] [PMID: 27028556]
[79]
Karamlou, K.; Gorn, A.H. Refractory sweet syndrome with autoimmune organizing pneumonia treated with monoclonal antibodies to tumor necrosis factor. J. Clin. Rheumatol., 2004, 10(6), 331-335.
[http://dx.doi.org/10.1097/01.rhu.0000147053.60795.46] [PMID: 17043542]
[80]
Watson, I.T.; Haugh, I.; Gardner, A.R.; Menter, M.A. Histiocytoid Sweet syndrome successfully treated with etanercept. Proc. Bayl. Univ. Med. Cent., 2018, 31(3), 347-349.
[http://dx.doi.org/10.1080/08998280.2018.1460132] [PMID: 29904308]
[81]
Ambrose, N.L.; Tobin, A.M.; Howard, D. Etanercept treatment in Sweet’s syndrome with inflammatory arthritis. J. Rheumatol., 2009, 36(6), 1348-1349.
[http://dx.doi.org/10.3899/jrheum.080698] [PMID: 19509095]
[82]
Yamauchi, P.S.; Turner, L.; Lowe, N.J.; Gindi, V.; Jackson, J.M. Treatment of recurrent Sweet’s syndrome with coexisting rheumatoid arthritis with the tumor necrosis factor antagonist etanercept. J. Am. Acad. Dermatol., 2006, 54(3)(Suppl. 2), S122-S126.
[http://dx.doi.org/10.1016/j.jaad.2005.11.1089] [PMID: 16488324]
[83]
Kluger, N.; Gil-Bistes, D.; Guillot, B.; Bessis, D. Efficacy of anti-interleukin-1 receptor antagonist anakinra (Kineret®) in a case of refractory Sweet’s syndrome. Dermatology (Basel), 2011, 222(2), 123-127.
[http://dx.doi.org/10.1159/000326112] [PMID: 21464561]
[84]
Delluc, A.; Limal, N.; Puéchal, X.; Francès, C.; Piette, J.C.; Cacoub, P. Efficacy of anakinra, an IL1 receptor antagonist, in refractory Sweet syndrome. Ann. Rheum. Dis., 2008, 67(2), 278-279.
[http://dx.doi.org/10.1136/ard.2006.068254] [PMID: 18192308]
[85]
Shahid, Z.; Kalayanamitra, R.; Patel, R.; Groff, A.; Jain, R. Refractory Sweet syndrome treated with anakinra. Cureus, 2019, 11(4)e4536
[PMID: 31263644]
[86]
Nestor, L.A.; Tobin, A.M. Oral Sweet’s syndrome occurring in ulcerative colitis. BMJ Case Rep., 2017.
[87]
Banse, C.; Sobocinski, V.; Savoye, G.; Avenel, G.; Vittecoq, O. Occurrence of Sweet syndrome under anti-TNF. Clin. Rheumatol., 2015, 34(11), 1993-1994.
[http://dx.doi.org/10.1007/s10067-015-3054-3] [PMID: 26292633]
[88]
Bruscino, N.; Grandi, V.; Gunnella, S.; Maio, V. Sweet’s syndrome in a patient affected by ankylosing spondylitis and ulcerative colitis under treatment with adalimumab. J. Eur. Acad. Dermatol. Venereol., 2016, 30(1), 195-196.
[http://dx.doi.org/10.1111/jdv.12710] [PMID: 25201185]
[89]
Keidel, S.; McColl, A.; Edmonds, S. Sweet’s syndrome after adalimumab therapy for refractory relapsing polychondritis. BMJ Case Rep., 2011, 2011
[http://dx.doi.org/10.1136/bcr.10.2011.4935]
[90]
Doolan, B.J.; Cranwell, W.C.; Nicolopoulos, J.; Dolianitis, C. Topical dapsone gel for treatment of axillary subcorneal pustular dermatosis. J. Dermatol., 2019, 46(11), e437-e438.
[http://dx.doi.org/10.1111/1346-8138.14953] [PMID: 31232481]
[91]
Ceccarelli, G.; Molinelli, E.; Campanati, A.; Goteri, G.; Offidani, A. Sneddon-Wilkinson disease and monoclonal gammopathy of undetermined significance in the elderly: Case report. Case Rep. Dermatol., 2019, 11(2), 209-214.
[http://dx.doi.org/10.1159/000487003] [PMID: 31427943]
[92]
Yamaguchi, Y.; Oyama, N.; Koizumi, H.; Chino, T.; Hasegawa, M. Successful treatment of recalcitrant subcorneal pustular dermatosis with oral nicotinamide. J. Dermatol., 2019, 46(11), e438-e440.
[http://dx.doi.org/10.1111/1346-8138.14980] [PMID: 31187880]
[93]
Falcone, L.M.; Pilcher, M.F.; Kovach, R.F.; Powers, R. Pentoxyfilline as a treatment for subcorneal pustular dermatosis. Dermatol. Ther. (Heidelb.), 2019, 32(2)e12818
[http://dx.doi.org/10.1111/dth.12818] [PMID: 30637905]
[94]
Voigtländer, C.; Lüftl, M.; Schuler, G.; Hertl, M. Infliximab (anti-tumor necrosis factor alpha antibody): A novel, highly effective treatment of recalcitrant subcorneal pustular dermatosis (Sneddon-Wilkinson disease). Arch. Dermatol., 2001, 137(12), 1571-1574.
[http://dx.doi.org/10.1001/archderm.137.12.1571] [PMID: 11735706]
[95]
Naretto, C.; Baldovino, S.; Rossi, E.; Spriano, M.; Roccatello, D. The case of SLE associated Sneddon-Wilkinson pustular disease successfully and safely treated with infliximab. Lupus, 2009, 18(9), 856-857.
[http://dx.doi.org/10.1177/0961203309103053] [PMID: 19578113]
[96]
Bonifati, C.; Trento, E.; Cordiali, F.P.; Muscardin, L.; Amantea, A.; Carducci, M. Early but not lasting improvement of recalcitrant subcorneal pustular dermatosis (Sneddon-Wilkinson disease) after infliximab therapy: Relationships with variations in cytokine levels in suction blister fluids. Clin. Exp. Dermatol., 2005, 30(6), 662-665.
[http://dx.doi.org/10.1111/j.1365-2230.2005.01902.x] [PMID: 16197383]
[97]
Raimondo, N.; Gonzalez, L.; Orden, A.; Carvalho, A. Sneddon Wilkinson syndrome: A therapeutic challenge. Poster abstract presented at the American Academy of Dermatology 65th Annual Meeting. J. Am. Acad. Dermatol., 2007, 56, AB46.
[98]
Berk, D.R.; Hurt, M.A.; Mann, C.; Sheinbein, D. Sneddon-Wilkinson disease treated with etanercept: Report of two cases. Clin. Exp. Dermatol., 2009, 34(3), 347-351.
[http://dx.doi.org/10.1111/j.1365-2230.2008.02905.x] [PMID: 18699836]
[99]
Iobst, W.; Ingraham, K. Sneddon-Wilkinson disease in a patient with rheumatoid arthritis. Arthritis Rheum., 2005, 52(12), 3771.
[http://dx.doi.org/10.1002/art.21402] [PMID: 16329105]
[100]
Bedi, M.K. Successful treatment of long-standing, recalcitrant subcorneal pustular dermatosis with etanercept. Skinmed, 2007, 6(5), 245-247.
[http://dx.doi.org/10.1111/j.1540-9740.2007.888109.x] [PMID: 17786105]
[101]
de Encarnação, Roque Diamantino F,; Dias, Coelho JM, Macedo; Ferreira AM, ; Macedo, F.A.M.; Fidalgo, A.I. Subcorneal pustular dermatosis treated successfully with adalimumab. Eur. J. Dermatol., 2010, 20(4), 512-514.
[http://dx.doi.org/10.1684/ejd.2010.0957] [PMID: 20395190]
[102]
Versini, M.; Mantoux, F.; Angeli, K.; Passeron, T.; Lacour, J.P. Maladie de Sneddon-Wilkinson échappant à l’infliximab et à l’étanercept: Efficacité de l’adalimumab. Ann. Dermatol. Venereol., 2013, 140(12), 797-800.
[http://dx.doi.org/10.1016/j.annder.2013.07.012] [PMID: 24315227]
[103]
Sauder, M.B.; Glassman, S.J. Palmoplantar subcorneal pustular dermatosis following adalimumab therapy for rheumatoid arthritis. Int. J. Dermatol., 2013, 52(5), 624-628.
[http://dx.doi.org/10.1111/j.1365-4632.2012.05707.x] [PMID: 23489057]
[104]
Jorizzo, J.L.; Apisarnthanarax, P.; Subrt, P. Bowel-bypass syndrome without bowel bypass. Bowel-associated dermatosis-arthritis syndrome. Arch. Intern. Med., 1983, 143(3), 457-461.
[http://dx.doi.org/10.1001/archinte.1983.00350030071013] [PMID: 6830382]
[105]
Ely, P.H. The bowel bypass syndrome: A response to bacterial peptidoglycans. J. Am. Acad. Dermatol., 1980, 2(6), 473-487.
[http://dx.doi.org/10.1016/S0190-9622(80)80148-4] [PMID: 7400404]
[106]
Oldfield, C.W.; Heffernan-Stroud, L.A.; Buehler-Bota, T.S.; Williams, J.V. Bowel-associated dermatosis-arthritis syndrome (BADAS) in a pediatric patient. JAAD Case Rep., 2016, 2(3), 272-274.
[http://dx.doi.org/10.1016/j.jdcr.2016.05.012] [PMID: 27486592]
[107]
Thrash, B.; Patel, M.; Shah, K.R.; Boland, C.R.; Menter, A. Cutaneous manifestations of gastrointestinal disease: Part II. J. Am. Acad. Dermatol., 2013, 68(2), 211.e1-211.e33.
[http://dx.doi.org/10.1016/j.jaad.2012.10.036] [PMID: 23317981]
[108]
Truchuelo, M.T.; Alcántara, J.; Vano-Galván, S.; Jaén, P.; Moreno, C. Bowel-associated dermatosis-arthritis syndrome: Another cutaneous manifestation of inflammatory intestinal disease. Int. J. Dermatol., 2013, 52(12), 1596-1598.
[http://dx.doi.org/10.1111/j.1365-4632.2011.05149.x] [PMID: 22640167]
[109]
Dodd, E.M.; Howard, J.R.; Dulaney, E.D.; Rosenthal, S.I.; Wanna, M.R.; Farah, R.S. Pyodermatitis-pyostomatitis vegetans associated with asymptomatic inflammatory bowel disease. Int. J. Dermatol., 2017, 56(12), 1457-1479.
[http://dx.doi.org/10.1111/ijd.13640] [PMID: 28474357]
[110]
Clark, L.G.; Tolkachjov, S.N.; Bridges, A.G.; Camilleri, M.J. Pyostomatitis vegetans (PSV)-Pyodermatitis vegetans (PDV): A clinicopathologic study of 7 cases at a tertiary referral center. J. Am. Acad. Dermatol., 2016, 75(3), 578-584.
[http://dx.doi.org/10.1016/j.jaad.2016.03.047] [PMID: 27349819]
[111]
Bertlich, I.; Gauss, A.; Schäkel, K.; Enk, A.; Hoffmann, J.H.O. Pyodermatitis-pyostomatitis vegetans with histological and immunohistological aspects of autoimmune blistering disease treated with infliximab. J. Dtsch. Dermatol. Ges., 2019, 17(5), 540-542.
[http://dx.doi.org/10.1111/ddg.13830] [PMID: 30933427]
[112]
Mijandrusić-Sincić, B.; Licul, V.; Gorup, L.; Brncić, N.; Glazar, I.; Lucin, K. Pyostomatitis vegetans associated with inflammatory bowel disease-report of two cases. Coll. Antropol., 2010, 34(Suppl. 2), 279-282.
[PMID: 21305742]
[113]
Brinkmeier, T.; Frosch, P.J. Pyodermatitis-pyostomatitis vegetans: A clinical course of two decades with response to cyclosporine and low-dose prednisolone. Acta Derm. Venereol., 2001, 81(2), 134-136.
[http://dx.doi.org/10.1080/00015550152384290] [PMID: 11501652]
[114]
Marzano, A.V.; Borghi, A.; Wallach, D.; Cugno, M. A comprehensive review of neutrophilic diseases. Clin. Rev. Allergy Immunol., 2018, 54(1), 114-130.
[http://dx.doi.org/10.1007/s12016-017-8621-8] [PMID: 28688013]
[115]
Lim, Y.L.; Ng, S.K.; Lian, T.Y. Amicrobial pustulosis associated with autoimmune disease in a patient with Sjögren syndrome and IgA nephropathy. Clin. Exp. Dermatol., 2012, 37(4), 374-378.
[http://dx.doi.org/10.1111/j.1365-2230.2011.04262.x] [PMID: 22300247]
[116]
Wang, M.Z.; Camilleri, M.J.; Guo, R.; Wieland, C.N. Amicrobial pustulosis of the folds: Report of 4 cases. J. Cutan. Pathol., 2017, 44(4), 367-372.
[http://dx.doi.org/10.1111/cup.12873] [PMID: 28000249]
[117]
Marzano, A.V.; Tavecchio, S.; Berti, E.; Gelmetti, C.; Cugno, M. Paradoxical autoinflammatory skin reaction to tumor necrosis factor alpha blockers manifesting as amicrobial pustulosis of the folds in patients with inflammatory bowel diseases.Medicine, (Baltimore), 2015, 94(45)e1818.
[http://dx.doi.org/10.1097/MD.0000000000001818] [PMID: 26559252]
[118]
Al-Raddadi, R.; Frances, C.; Moguelet, P.; Bachmeyer, C.; Guégan, S. Ustekinumab as effective treatment for refractory amicrobial pustulosis of the folds associated with Crohn’s disease. Acta Derm. Venereol., 2017, 97(3), 389-390.
[http://dx.doi.org/10.2340/00015555-2544] [PMID: 27722763]
[119]
Amazan, E.; Ezzedine, K.; Mossalayi, M.D.; Taieb, A.; Boniface, K.; Seneschal, J. Expression of interleukin-1 alpha in amicrobial pustulosis of the skin folds with complete response to anakinra. J. Am. Acad. Dermatol., 2014, 71(2), e53-e56.
[http://dx.doi.org/10.1016/j.jaad.2013.12.041] [PMID: 25037815]
[120]
Lee, H.Y.; Pelivani, N.; Beltraminelli, H.; Hegyi, I.; Yawalkar, N.; Borradori, L. Amicrobial pustulosis-like rash in a patient with Crohn’s disease under anti-TNF-alpha blocker.Dermatology, (Basel), 2011, 222(4), 304-310.
[http://dx.doi.org/10.1159/000329428] [PMID: 21757882]
[121]
André, M.F.; Piette, J.C.; Kémény, J.L. French Study Group on Aseptic Abscesses. French Study Group on aseptic abscesses. Aseptic abscesses: A study of 30 patients with or without inflammatory bowel disease and review of the literature. Medicine (Baltimore), 2007, 86(3), 145-161.
[http://dx.doi.org/10.1097/md.0b013e18064f9f3] [PMID: 17505254]
[122]
Ito, T.; Sato, N.; Yamazaki, H.; Koike, T.; Emura, I.; Saeki, T. A case of aseptic abscesses syndrome treated with corticosteroids and TNF-alpha blockade. Mod. Rheumatol., 2013, 23(1), 195-199.
[http://dx.doi.org/10.3109/s10165-012-0640-y] [PMID: 22526827]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 22
ISSUE: 1
Year: 2021
Published on: 02 May, 2020
Page: [46 - 58]
Pages: 13
DOI: 10.2174/1389201021666200503050803
Price: $65

Article Metrics

PDF: 54
HTML: 4